// App-Quantinova.ai

: Preclinical Studies of Chiauranib Inhibit Follicular Lymphoma through VEGFR2/ERK/STAT3 Signaling Pathway

Researchers

Presenter

  • Yuanfang Tang

Principal Investigators

  • Mengya Zhong

  • Jie Zha

  • Bing Xu

Medical Centers

  • The First Affiliated Hospital of Xiamen University, xiamen, China

  • Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China

  • Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, xiamen, China

  • Department of Hematology, The first Affiliated Hosptial of Xiamen University, Xiamen, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • Solid malignancies

  • Non‐Hodgkin Lymphoma

  • Lymphomas

Biomarkers

  • B-cell lymphoma 2

  • Colony stimulating factor 1 receptor

  • Extracellular signal-regulated kinase

  • Signal transducer and activator of transcription 3

  • Kinase Insert Domain Receptor

Drug/Treatment

  • chiauranib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved